Current issue #17, 2016

A State Duma deputy to oversee AIPM

The top management of Biocad (St. Petersburg) suggested that State Duma deputy Alexander Petrov from Ekaterinburg examined the activities of the International Association of Pharmaceutical Manufacturers (AIPM). Biocad accuses the association of destabilizing the Russian pharma market. The company believes that the AIPM makes propaganda against Russian manufacturers and hampers their development by underpricing the products of the association’s members.

[PharmVestnik # 17, 17/05/2016, p. 1, cont’d p. 2]

A Russian manufacturer files a bunch of applications for signing special investment agreements

Biocad filed with the Ministry of Industry and Trade 17 applications regarding the attribution of a number of their drugs to medicinal products having no local analogs. None of these drugs have been registered by the company so far, but Biocad plans to do so. In order to check Biocad’s data, the ministry forwarded the company’s applications to three professional associations. Now the entire industry is aware of the manufacturer’s R&D advances.

[PharmVestnik # 17, 17/05/2016, p. 3]

“Odd-man-out” proved to be a fool

Local player preference regulation results in losses in bidding

Distributors came across new issues when implementing the “odd-man-out” regulation. Pursuant to this regulation, they are facing fines if their applications are rejected more than twice a quarter. The wholesalers are so much disappointed that they have already applied to the Ministry of Economic Development. They confirmed at the ministry that they were aware of the problem and that they had already made certain efforts to remove it.

[PharmVestnik # 17, 17/05/2016, p. 4]

A problem of growth

Experts remark on overabundance of pharmacies

The number of pharmacies and pharmacy points in Russia ha...